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Purpose: Atherosclerosis (AS) and osteoporosis (OP) are common causes of morbidity and 
mortality in postmenopausal women and are connected via an unknown mechanistic link. 
Metabolite profiling of blood samples may allow the identification of new biomarkers and 
pathways for this enigmatic association.
Patients and Methods: We studied the difference in 148 metabolite levels from serum samples 
in postmenopausal women with AS and OP compared with those in healthy participants in this 
cross-sectional study. Quantitative AS was assessed by carotid artery intima-media thickness 
(cIMT) and carotid artery calcifications (CACs) by ultrasound, as well as OP by femoral neck 
(FN) bone mineral density (BMD) and 148 metabolic measures with high-throughput proton (1H) 
nuclear magnetic resonance (NMR) in serum samples from 280 postmenopausal (PM) women. 
Subjects were a randomly selected subsample from the population-based Kuopio Osteoporosis 
Risk Factor and Prevention (OSTPRE) study. The final study population included the following 
groups: OP with CAC (n=16, group I), non-OP with no CAC (n=59, group II), high cIMT tertile 
with OP (n=11, group III) and low cIMT tertile without OP (n=48, group IV).
Results: There were differences in several metabolite levels between groups I and II. The 
acetate level was lower in group I compared to that in group II (group I mean ± SD: 0.033 ± 
0.0070; group II: 0.041 ± 0.014, CI95%: 0.018‒0.15, p=0.014). The result was similar with 
diacylglycerol (p=0.002), leucine (p=0.031), valine (p=0.022) and several very low-density 
lipoprotein (VLDL) metabolite levels, which were lower in group I compared to those in 
group II. However, no associations were found in adjusted analyses with total body (TB) fat 
mass (FM), age and statin use (p>0.05).
Conclusion: Our novel study found differences in the metabolite profiling of altered amino 
acid and lipoprotein metabolism in participants with OP and AS compared with those in 
healthy women. The causative mechanisms remain unknown and further studies are needed.
Keywords: metabolomics, carotid artery calcification, postmenopausal women, 
osteoporosis, carotid intima-media thickness, acetate
Introduction
Previously, low bone mineral density (BMD) has been shown to be an independent 
predictor of the development of atherosclerosis (AS) in elderly individuals.1–3 The 
underlying mechanisms are unknown, but indirect associations via genetics or the 
environment have been suggested.4
Metabolic profiling of serum samples is possible by nuclear magnetic resonance 
(NMR) spectrometry, which is a novel technology for the profiling of small 
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molecules (metabolites) and proteins.5 NMR offers multi-
faceted approaches to detect and identify a variety of 
metabolites and accurately measure their concentrations.6 
The application of metabolomics in osteoporosis (OP) 
could provide researchers the opportunity to gain new 
insight into the metabolic profiling and pathophysiological 
mechanisms.
Differences in plasma lipid levels or their modifications, 
such as oxidation, have been suggested as a link between 
BMD and AS.4,7 In previous studies with mice, the oxidized 
lipids inhibited the differentiation of osteoblasts.8 On the 
other hand, oxidized low-density lipoprotein (OxLDL) par-
ticles were phagocyted much faster in macrophages than in 
non-OxLDL particles and OxLDLs are known to be present 
in plasma in AS, both in human and animal models.9 
Although these findings have not been confirmed in all 
studies and the role of antioxidants is controversial, espe-
cially in preventing AS.9–11
Considering the other lipid particles, subjects with low 
BMD showed higher high-density lipoprotein (HDL) choles-
terol levels in the Asian population.12,13 In general, HDL 
protects against the development of AS by enhancing reverse 
cholesterol removal.10,14 Elevated LDL cholesterol levels are 
causally related to the development of AS,9 and elevated 
LDL cholesterol levels have been associated, albeit weakly, 
with lower BMD.7 However, contrasting results have also 
been shown.15 Furthermore, qualitative changes in LDL 
particles, such as oxidation, promote osteoporotic bone loss 
by directing progenitor marrow mesenchymal stromal cells 
to differentiate into adipogenic lineages instead of osteogenic 
differentiation, in line with “the lipid hypothesis of 
osteoporosis”.16 In previous population-based studies, meta-
bolite profiling, including lipid profiling, has found new 
biomarkers beyond conventional cardiovascular disease 
(CVD) risk markers,17 and similar biomarker associations 
with BMD have also been found.18 In previous studies, 
monounsaturated fatty acids (MUFA) and phenylalanine 
have been associated with a higher risk for CVD events,17 
and CYP3A5 and SULT2A1 genetic loci were found to be 
important in the regulation of metabolites causing OP.18
In relation to our subject, a few studies have compared 
metabolic profiles between osteoporotic and normal BMD 
populations; these have suggested differences between the 
groups.19,20 For example, the dipeptide Gly-Gly and 
cysteine levels were significantly lower in the low BMD 
group compared to those in the normal BMD group in 
Japanese women aged between 39 and 64, but BMD was 
assessed with ultrasound.19
We have previously shown that postmenopausal (PM) 
osteoporotic women have more carotid artery calcifica-
tions (CACs) compared to those in PM women with nor-
mal BMD.2 Our aim was to study the differences in 148 
metabolite levels between women with OP and AS com-
pared with those in healthy PM women without these 
ailments in this cross-sectional study.
Patients and Methods
Population
This Kuopio Osteoporosis Risk Factor and Prevention- 
Bone, Brain, and Atherosclerosis (OSTPRE-BBA) study 
was performed to study the associations between brain 
function, bone and adiposity in 458 randomly selected 
PM women from the original OSTPRE study population. 
This study population is a random subsample from the 
original OSTPRE study cohort (n=14,220). The final 
study sample (n=280) included women who participated 
in carotid ultrasound measurements (2009), BMD mea-
surements (2009–2011) and gave a blood sample (2009) 
for the NMR analyses (2014). In total, 168 women were 
excluded, because they did not attend either ultrasound or 
DXA measurement, and 10 serum samples were excluded 
for a number of reasons in metabolomics sampling quality 
checks (2014); five of the samples were missing, three 
samples had high ethanol levels due to the sampling pro-
cess, one sample had a low protein level, and one sample 
had a quality problem. The population selection process 
was previously described in detail2 and is shown in 
Figure 1.
All participants provided informed written consent. 
The North Savo Health Care District Ethics Committee 
approved this study (number 112/2009), and the study 
complies with the Declaration of Helsinki.
Carotid Ultrasound and Carotid 
Intima-Media Thickness (cIMT) 
Measurements
Carotid ultrasound and cIMT measurements were carried 
out on 346 OSTPRE-BBA participants in 2009 at the 
Kuopio Musculoskeletal Research Unit (KMRU) at the 
University of Eastern Finland, Kuopio, using the Technos 
MP ESAOTE ultrasound device (Esaote, Italy) with 
a B-type linear transducer at a frequency of 9 MHz. IMT 
was measured over a 1 cm long segment from the distal 
common carotid artery (CCA) just before the bifurcation, 
as described previously.2
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Two IMT measurements were established and used 
herein: CAC and the maximum cIMT. CACs were cate-
gorized into two different groups: the presence or absence 
of calcifications. The maximum cIMT variable was formed 
from the highest cIMTs in both carotid arteries (the aver-
age of both). It was used to demonstrate the highest 
protrusion in the lumen and quantitative AS.
BMD and Body Composition
Total body (TB) fat mass (FM) (kg) and femoral neck (FN) 
BMD (g/cm2) were measured using DXA in 2009–2011 for 
290 participants whose cIMTs were measured previously.2 
Measurements were carried out by trained personnel at the 
University of Eastern Finland, KMRU, using the General 
Electric Lunar Prodigy DXA device (Madison, WI, USA).
Figure 1 Population selection process.
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Blood Sampling and NMR Spectrometry
All blood samples were overnight fasting samples. 
Samples were taken at local health-care centers in 2009 
and frozen at −80°C. The final number of analyzed serum 
samples was 280. A total of 10 blood samples were 
excluded for a number of reasons; the ethanol level was 
high in three samples due to the sampling process, the 
protein level was low in one sample, one sample had 
a quality problem and five of the samples were missing.
A high-throughput proton (1H) NMR spectrometry 
metabolomics platform was used at the University of 
Eastern Finland in 2014 to quantify up to 148 metabolic 
phenotypes from serum samples that represent systemic 
metabolism.6 The measured samples included multiple 
metabolic variables, including lipoprotein lipids and sub-
classes, fatty acids and fatty acid compositions, amino 
acids and glycolysis precursors. Briefly, in NMR spectro-
scopy, each molecule containing hydrogen atoms gives 
a specific signal in a magnetic field and the concentration 
and composition of the molecule can be quantified through 
these signals.21
First, the frozen samples were handled in plates, which 
included quality control samples. Control samples were 
used as a technical reference to monitor the performance 
of the automated liquid handler and spectrometer and to 
monitor the consistency of quantifications. A sodium phos-
phate buffer (75 mmol/L Na2HPO4 in 80%/20% H2O/D2 
O, pH 7.4; also including 0.08% sodium 3-(trimethylsilyl) 
propionate-2,2,3,3-d4 and 0.04% sodium azide) was mixed 
into the sample before the NMR measurements (260 μL of 
serum and 260 μL of a buffer). The PerkinElmer JANUS 
Automated Workstation was used to handle the samples. 
Bruker AVANCE III 500 MHz and Bruker AVANCE III 
HD 600 MHz spectrometers were used for NMR metabo-
lomics laboratory setup. The data were collected automa-
tically with the 600 MHz or the 500 MHz spectrometer. 
Standardized parameters were used for data acquisitions. 
After these measurements, the same samples went through 
a standardized lipid extraction procedure based on extrac-
tion steps. The extraction procedure was done manually 
using an Integra Biosciences VIAFLO 96 channel electro-
nic pipette. The lipid extracts were moved into the NMR 
tubes and the extracted lipid data were collected with the 
600 MHz instrument using a standard parameter set. The 
raw data processing was done automatically, and it 
included overall signal check for missing/extra peaks, 
baseline removal, spectral area-specific signal alignments 
and background control. For the raw data that passed all 
the quality control steps, regression modelling was per-
formed to produce the actual molecular data. In addition, 
the individual metabolic measurements underwent various 
statistical quality control phases. After quality control, the 
metabolomic data were formed.21
In this data, all of the lipid particles (very low-density 
lipoprotein [VLDL], intermediate-density lipoprotein [IDL], 
LDL, and HDL) were grouped according to size (extremely 
large and chylomicrons, large, medium, small, and extra 
small). In addition, concentration, total cholesterol, choles-
terol esters, free cholesterol, triglycerides, total lipids and 
phospholipids were separately grouped according to the size 
of the lipid particles. The currently applied NMR-based 
metabolic profiling has been used in various recent epide-
miological and genetic studies; the method and process used 
in this study were previously described in detail.6,21 Batch 
effect was minimized by quality checks during the sample 
analysis and using linear models in statistical analyses (see 
statistical analyses section).
The full metabolite list is provided in Supplementary 
Table 1.
Other Variables
Weight and height were measured in connection with the 
DXA densitometry. The body mass index (BMI) was 
calculated as body weight/height2 (kg/m2). Current smok-
ing habits (no/yes), physical exercise with shortness of 
breath (hours in a week) and medications were based on 
a postal enquiry in 2009, with the question on chronic 
health disorders being verified by a physician.
Statistical Analyses
Values are expressed as the percentage or mean ± SD. The 
Kolmogorov–Smirnoff test or histogram inspections were 
used to ensure the normality of the variables. All of the 
participants (n=280) were divided into the groups according 
to their cIMT (low, middle, or high tertiles), CAC (no, yes) 
and T-score (OP, osteopenia and normal) status. Group 
I included participants with OP (FN BMD, T-score ≤-2.5 
SD) and CAC (n=16); group II included participants with 
normal T-scores and no CAC (n=59), so it was used as 
a control group; group III (n=11) included participants with 
the highest cIMT tertiles and OP; and group IV (n=48) 
included participants with the lowest cIMT tertiles and nor-
mal T-scores, so it was used as a control group. All other 
groups were excluded. Student’s t-test was used to study the 
differences in metabolite levels between groups I–II and III– 
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IV, respectively. Similar analysis models were applied in 
univariate analysis using metabolite levels as a dependent 
variable and the dichotomic group I–II or III–IV variable as 
an independent variable, adjusted by age (years), TB FM (kg) 
and statin use (no/yes). Adjusted analyses were undertaken if 
p<0.10. The false discovery rate (FDR) was used to control 
for false-positive errors when a high number of analyses were 
performed. p<0.05 was considered statistically significant.
Results
The mean age of the study population was 73.6 ± 2.8 years. 
Overall, 23.6% of women were obese (BMI >30 kg/m2) and 
3.6% of women were current smokers. CACs were found in 
168 (60%) cases. Regarding the use of drugs, 6.1% of 
patients used OP medication, 4.6% used inhaled corticoster-
oids and 1.7% used corticosteroids orally. The FM and BMI 
were significantly lower in groups I and III compared to 
those in groups II and IV (Table 1).
Metabolomic Distinction Between BMD 
and CAC
The differences in metabolite levels between the osteoporo-
tic subjects with CAC (group I, n=16) compared to those 
with normal T-scores and no CAC (group II, n=59) are 
shown in Figure 2. In group 1, the metabolite levels were 
significantly lower in the majority of the VLDL particles 
measured and diacylglycerol, apolipoprotein B (APOB), 
leucine, valine and acetate levels (p<0.05). All of the asso-
ciations vanished after adjustments (Figure 2). In addition, 
there were no differences in the ratio of phenylalanine to 
tyrosine between the groups (p>0.05).
Metabolomic Distinction Between BMD 
and cIMT
When the high cIMT tertile and OP group (group III, 
n=11) was compared with the low cIMT tertile and normal 
BMD group (group IV, n=48), only free cholesterol in very 
large VLDL and diacylglycerol and acetate levels were 
slightly lower in group III (p<0.05). All associations van-
ished after adjustments for age, TB FM and statin use. In 
addition, there were no differences in the ratio of pheny-
lalanine to tyrosine between the groups (p>0.05). The 
exact results are shown in Figure 3.
False discovery rate (FDR) analyses were performed 
for all metabolic variables, but no associations were found 
(data not shown).
We noticed that levels of alanine, glutamine and lactate 
were slightly higher and the levels of histidine, acetate and 
acetoacetate were lower in our study sample compared to 
those in the larger OSTPRE populations.
Supplementary Table 1 shows all the numerical meta-
bolite levels in groups I to IV.
Table 1 Characteristics of the Study Population and the Subgroups
Characteristics Whole Sample 
(n=280) Mean ± SD
Group 1 (n= 16) 
Mean ± SD
Group 2 (n=59) 
Mean ± SD
pa Group 3 (n=11) 
Mean ± SD
Group 4 (n=48) 
Mean ± SD
pb
Age (years) 73.6 ± 2.8 74.6 ± 2.4 72.6 ± 2.7 0.007 74.8 ± 2.5 72.6 ± 2.8 0.017
BMI (kg/m2) 28.8 ± 4.0 25.2 ± 3.7 29.2 ± 4.6 0.002 25.4 ± 3.8 29.9 ± 5.1 0.008
FN T-score −1.1 ± 1.1 −2.8 ± 0.3 −0.1 ± 0.8 −2.9 ± 0.3 −0.04 ± 0.9
Maximum cIMT (mm) 2.05 ± 0.66 2.6 ± 0.8 1.5 ± 0.3 0.001 2.9 ± 0.8 1.4 ± 0.2
TB fat mass (kg) 29.2 ± 9.3 22.4 ± 7.0 30.5 ± 8.8 0.001 22.4 ± 6.5 31.9 ± 9.8 0.003
Shortness of breath in 
a week (hours)c
0.98 ± 1.23 1.04 ± 1.93 1.10 ± 1.27 0.867 0.33 ± 0.58 1.00 ± 1.18 0.010
Whole sample (n=280) 
n (%)
Group 1 n (%) Group 2 n (%) Group 3 n (%) Group 4 n (%)
Statin users 132 (47.1) 12 (75.0) 26 (44.1) 0.028 9 (81.8) 21 (43.8) 0.023
Type 2 diabetes 24 (8.6) 0 (0.0) 5 (8.5) 0.228 0 (0.0) 4 (8.3) 0.321
HT users 26 (9.3) 2 (12.5) 8 (13.6) 0.912 1 (9.1) 5 (10.4) 0.896
Abbreviations: Group 1, subject with osteoporosis and carotid artery calcifications (CAC); Group 2, subjects with normal T-score and no CAC; Group 3, subjects with 
osteoporosis and highest cIMT tertile; Group 4, subjects with normal T-score and lowest cIMT tertile; BMI, body mass index; FN, femoral neck; TB, total body; BMD, bone 
mineral density; cIMT, carotid intima-media thickness; HT, postmenopausal hormone therapy; pa, p-value between group 1 and 2; pb, p-value between group 3 and 4; c, 
physical exercise causing shortness of breath (hours in a week).
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Discussion
To the best of our knowledge, this is the first study to compare 
metabolic profiles between the well-established markers of AS 
and OP derived from a population-based study on PM women. 
With NMR, we were able to verify almost 150 lipid subclasses 
and amino acids and study the possible associations between 
amino acid and lipoprotein metabolite levels between women 
with a presence of CAC, high cIMT and low BMD compared 
to those in healthy women.
The methods used in this study, including DXA,22 
carotid ultrasound,23 and NMR,21 are widely used methods 
to measure BMD, cIMT and metabolite profile. NMR is 
not the most sensitive method for metabolite detection 
when compared with that of mass spectrometry. The mea-
surement time is only a few minutes but is sufficient to 
quantitatively capture analyses from a serum sample.21
We have previously shown that subjects with OP have 
more CACs than subjects without OP.2 It has been shown that 
elevated LDL and low HDL levels are associated with arter-
ial calcifications.24 As shown by our results, several VLDL 
particle subgroup levels were significantly lower in the OP 
and CAC group, but no differences were found with other 
cholesterol particles, including IDL, LDL and VLDL sub-
classes. Previously, VLDL has been positively associated 
with CAC in patients with diabetes,25 which is a result the 
opposite of ours, but the number of diabetics in our study was 
Figure 2 The differences in metabolomics between group I and group II. 
Notes: The mean difference in the 95% confidence intervals between group I (n=16, osteoporosis with CACs) and group II (n=59, normal T-score and no CACs). Group II 
was used as a reference group. Only the five most remarkable variables (p-values) from each metabolic group are shown in the figure. Logarithm modifications were made to 
ensure the variables had normal distributions. P-values indicated with red color were statistically significant. P = p-value; adj = adjusted with age, total body fat mass and 
statin use.
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small. On the contrary, in the previous study of Turkish PM 
women, VLDL was not associated with vertebral fracture or 
OP.26 In our study, associations were found with the CAC 
groups only but not with the high cIMT group. This suggests 
that VLDL may reflect the link between bone loss and 
vascular calcifications. Lipid metabolism may be accelerated 
in subjects with CAC and OP compared with that in the 
healthy group, which could explain the low VLDL particle 
levels. However, adjustments with the use of statins wea-
kened the association in our study, which may be due to the 
effects of statins on lipoprotein metabolism.
Other lipid particles, such as APOB, have been pre-
viously associated with AS27,28 and predicted cardiovascular 
events in a 15-year follow-up study.17 Subjects carrying the 
mutations for a familial deficiency or distorted function of 
APOB-100 have been shown to have low BMD.28 These 
subjects have high LDL levels27 and obviously enhanced AS. 
However, independent associations between LDL and BMD 
have also been shown.28 An APOB-100 genetic deficiency 
has also been associated with coronary artery calcifications,27 
which is in line with our results considering CACs.
From the less well-studied biomarkers, amino acids 
and other metabolites, such as acetate, valine, leucine 
and diacylglycerol levels, were lower in the CAC and 
OP group than those in the healthy group. This pattern 
could represent a new metabolic pathway between OP and 
Figure 3 The differences in metabolomics between group III and group IV. 
Notes: The mean difference with the 95% confidence intervals between group III (n=11, osteoporosis with highest CIMT tertile) and group IV (n=48, normal T-score and 
low CIMT). Group IV was used as a reference group. Only the five most remarkable variables (p-values) from each metabolic group are shown in the figure. Logarithm 
modifications were made to ensure variables normal distributions. P-values indicated with red color were statistically significant. P = p-value; adj = adjusted with age, total 
body fat mass and statin use.
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CAC. Previously, higher leucine and valine dietary intakes 
have been associated with low BMD in spinal cord injury 
subjects,29 in contrast with our results. Thus, nutrition may 
explain this discrepancy. Short-term overfeeding seems to 
correlate positively with plasma levels of valine, leucine, 
phenylalanine and tyrosine,30 but it is not known how well 
the dietary patterns reflect the measured amino acid levels.
In previous population-based studies, metabolites have 
been associated with cardiovascular disease (CVD) risk.17 
For example, phenylalanine was associated with a higher 
risk of CVD events at a younger age in the FINRISK 
study,17 while phenylalanine showed a strong association 
with death from coronary heart disease, but not with 
stroke, in a meta-analysis.17 Our results showed no differ-
ences in phenylalanine levels between different CAC and 
BMD groups, but this does not mean that they would not 
be predictive factors during the follow-up. The FINRISK 
study also showed that tyrosine, lactate and pyruvate were 
associated with higher CVD risk and that citrate was 
protective in this regard,17 but we did not find any differ-
ences between the BMD and CAC groups considering 
these amino acids. In addition, we did not find any differ-
ences in the ratio of phenylalanine to tyrosine, which is in 
line with the FINRISK follow-up study.17 The ratio of 
phenylalanine to tyrosine has been suggested to describe 
phenylalanine hydroxylase activity, which has been pre-
viously associated with coronary artery disease.31 In 
a previous study, the acetate level was higher in patients 
with coronary stenosis and artery microvascular changes 
than in controls, although the number of participants was 
low (n=32).32 Previously, a high acetate level was thought 
to be a slightly protective factor for CVD events,17 and in 
our study, the acetate levels were lower in the OP with 
CAC group. However, one confounding factor may be the 
high level of statin use, which was very common in this 
population, particularly in group I with OP and CAC. 
Nevertheless, the acetate level increases with the HMG- 
CoA enzyme inhibition by statins, because acetate is used 
in the early steps of cholesterol formation.33
Considering the BMD, cIMT and metabolomics, it has 
been previously shown that an atherosclerotic lipid profile 
(high LDL cholesterol) is associated with low BMD.7 
However, a Korean study with 4613 premenopausal and 
2661 PM women showed no association with BMD and 
LDL or HDL.12 It is well known that cIMT is a well- 
established marker of both carotid and coronary AS, and it 
is therefore obvious that high LDL and low HDL levels 
have been associated with high cIMT or predict its 
progression.24,34 However, there were no differences in 
the lipid profiles between the cIMT and BMD groups. 
A confounding factor may be related to the long-term 
use of statins. The current use of statins is quite high in 
groups with AS and probably impacts on the results. 
Statins decrease LDL cholesterol levels while increasing 
HDL cholesterol and lowering triglycerides to a lesser 
extent; they may also increase BMD, as shown in 
a recently widely published epidemiological study.35
In our study, the amount of physical exercise was much 
lower in the cIMT and OP group than that in the healthy 
group, but no difference was found between the CAC 
groups. These data could be in line with the preventive 
effects of physical activity on AS and OP36 or because 
subjects with these disorders do not engage in exercise. On 
the other hand, physical activity may affect CAC and OP 
via mechanisms other than weight-bearing loading and 
cardiorespiratory fitness. To support this, no differences 
were previously found between physical exercise and cor-
onary artery calcium score, but the prevalence of coronary 
artery disease was still higher in the inactive group com-
pared to that in the active group.37
There were a few limitations of our study. First, the 
subjects of this study were elderly women forming part of 
the OSTPRE study, which is a representative population- 
based sample. The final study sample (n=280) consisted of 
a small part of the original OSTPRE study cohort 
(n=14,220), so the risk of selection bias should be consid-
ered. Regarding this issue, we have previously shown that 
the main data variables (FN, BMD and BMI) do not differ 
from the original OSTPRE study sample 2. Second, the 
small number of participants decreased the power of the 
study findings and may have also caused abnormal statis-
tical variations. Third, the high number of variables high-
lights the statistical coincidences and increases the FDR. 
Fourth, the cross-sectional design may reveal associations 
but is not indicative of causality. Fifth, we acknowledge 
the lack of dietary information. Finally, the study was 
carried out in Finnish PM women, so generalization to 
other ethnic groups will require verification.
Conclusion
In conclusion, our study showed that there were novel dif-
ferences in metabolite profiling between subjects with OP 
and AS compared with those in the group with normal BMD 
without AS. In particular, acetate, valine, leucine, diacylgly-
cerol and several VLDL particle levels were lower in sub-
jects with OP and CAC, suggesting that altered amino acid 
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and lipid metabolism may be linked to both disorders. Wide 
metabolomic analyses may provide a new insight for clinical 
practice to estimate the risk of possible cross-linking end-
points (eg, stroke or fracture in a population having OP or 
AS). In other words, change in certain metabolite levels may 
be a risk predictor for AS in patients having OP. Further, 
follow-up studies with larger samples are needed to verify 
the results and find the risk predictors.
Abbreviations
AS, atherosclerosis; OP, osteoporosis; cIMT, carotid intima- 
media thickness; CAC, carotid artery calcification; CVD, car-
diovascular disease; PM, postmenopausal; DXA, dual energy 
X-ray absorptiometry; CCA, common carotid artery; FDR, 
false discovery rate; MUFA, monounsaturated fatty acid; 
OSTPRE, Kuopio Osteoporosis Risk Factor and Prevention 
Study; OSTPRE-BBA, Kuopio Osteoporosis Risk Factor and 
Prevention Study – Bone, Brain and Atherosclerosis; 1H, 
proton; APOB, apolipoprotein B; HMG-CoA, 3-hydroxy- 
3-methylglutaryl-CoA; TB, total body; FN, femoral neck; 
FM, fat mass; BMD, bone mineral density; NMR, nuclear 
magnetic resonance; BMI, body mass index; HT, postmeno-
pausal hormone therapy; VLDL, very low density lipoprotein; 
IDL, intermediate density lipoprotein; LDL, low-density lipo-
protein; HDL, high-density lipoprotein.
Acknowledgments
We thank Jussi Paananen and Oskari Timonen for statis-
tical help with metabolomics data, Mika Alakorpela and 
Pasi Soininen for NMR analyses and Jarmo Tiikkainen for 
performing IMT measurements. We also thank Tuomas 
Selander for the help with statistical analyses.
Funding
Academy of Finland (Kröger H, grant number 250707), 
Kuopio University Hospital EVO-grants (Tuppurainen M, 
grant number 5302460), Kuopio University Hospital 
Funding (V.T.R. grant number 5203024), the Ministry of 
Education and Culture of Finland (grant numbers 116/626/ 
2012, 46/627/2011 and 93/627/2010), and Strategic 
Funding of the University of Eastern Finland (grant num-
ber 931053) provided funding for this study. The fore-
going grants were appropriated for the original OSTPRE 
study for 20- and 25-year follow-up measurements and 
analyses. Finnish Medical Society Duodecim grant of 
a young researcher (Eka Grant, 2016), abetment grant 
(grant number 2038) and Finnish Menopause Society 
personal grant (2018) were appropriated as personal grants 
for MV for his PhD thesis.
Disclosure
All authors report no conflict of interests in this work.
References
1. Tamaki J, Iki M, Hirano Y, et al. Low bone mass is associated with 
carotid atherosclerosis in postmenopausal women: the Japanese 
Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos 
Int. 2009;20(1):53–60. doi:10.1007/s00198-008-0633-z
2. Varri M, Tuomainen T-P, Honkanen R, et al. Carotid intima-media 
thickness and calcification in relation to bone mineral density in 
postmenopausal women—The OSTPRE-BBA study. Maturitas. 
2014;78(4):304–309. doi:10.1016/j.maturitas.2014.05.017
3. Ye C, Xu M, Wang S, et al. Decreased bone mineral density is an 
independent predictor for the development of atherosclerosis: 
a systematic review and meta-analysis. PLoS One. 2016;11(5): 
e0154740. doi:10.1371/journal.pone.0154740
4. Bagger YZ, Rasmussen HB, Alexandersen P, et al. Links between 
cardiovascular disease and osteoporosis in postmenopausal women: 
serum lipids or atherosclerosis per se? Osteoporos Int. 2007;18 
(4):505–512. doi:10.1007/s00198-006-0255-2
5. Ala-Korpela M, Kangas AJ, Soininen P. Quantitative high-throughput 
metabolomics: a new era in epidemiology and genetics. Genome 
Med. 2012;4(4):36. doi:10.1186/gm335
6. Soininen P, Kangas AJ, Wurtz P, et al. High-throughput serum 
NMR metabonomics for cost-effective holistic studies on systemic 
metabolism. Analyst. 2009;134(9):1781–1785. doi:10.1039/ 
b910205a
7. Makovey J, Chen JS, Hayward C, Williams FMK, Sambrook PN. 
Association between serum cholesterol and bone mineral density. 
Bone. 2009;44(2):208–213. doi:10.1016/j.bone.2008.09.020
8. Parhami F, Garfinkel A, Demer LL. Role of lipids in osteoporosis. 
Arterioscler Thromb Vasc Biol. 2000;20(11):2346–2348. doi:10.1161/ 
01.ATV.20.11.2346
9. Steinberg D. The LDL modification hypothesis of atherogenesis: an 
update. J Lipid Res. 2009;50(Supplement):S376–S381. doi:10.1194/ 
jlr.R800087-JLR200
10. Buizert PJ, van Schoor NM, Lips P, Deeg DJ, Eekhoff EM. Lipid 
levels: a link between cardiovascular disease and osteoporosis? 
J Bone Miner Res. 2009;24(6):1103–1109. doi:10.1359/jbmr. 
081262
11. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, 
Witztum JL. Nutrition Committee of the American 
Heart Association Council on Nutrition, Physical Activity, and 
Metabolism. Antioxidant vitamin supplements and cardiovascular 
disease. Circulation. 2004;110(5):637–641. doi:10.1161/01.CIR.00 
00137822.39831.F1
12. Jeong I-K, Cho SW, Kim SW, et al. Lipid profiles and bone mineral 
density in pre- and postmenopausal women in Korea. Calcif Tissue 
Int. 2010;87(6):507–512. doi:10.1007/s00223-010-9427-3
13. Li S, Guo H, Liu Y, et al. Relationships of serum lipid profiles and 
bone mineral density in postmenopausal Chinese women. Clin 
Endocrinol (Oxf). 2015;82(1):53–58. doi:10.1111/cen.12616
14. D’Amelio P, Di Bella S, Tamone C, et al. HDL cholesterol and bone 
mineral density in normal-weight postmenopausal women: is there 
any possible association? Panminerva Med. 2008;50(2):89–96.
15. Go J-H, Song Y-M, Park J-H, Park J-Y, Choi Y-H. Association 
between serum cholesterol level and bone mineral density at lumbar 
spine and femur neck in postmenopausal korean women. Korean 
J Fam Med. 2012;33(3):166–173. doi:10.4082/kjfm.2012.33.3.166
Vascular Health and Risk Management 2020:16                                                                          submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       
DovePress                                                                                                                         
523




































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
16. Parhami F, Jackson SM, Tintut Y, et al. Atherogenic diet and mini-
mally oxidized low density lipoprotein inhibit osteogenic and pro-
mote adipogenic differentiation of marrow stromal cells. J Bone 
Miner Res. 1999;14(12):2067–2078. doi:10.1359/jbmr.1999.14. 
12.2067
17. Wurtz P, Havulinna AS, Soininen P, et al. Metabolite profiling and 
cardiovascular event risk: A prospective study of 3 
population-based cohorts. Circulation. 2015;131(9):774–785. 
doi:10.1161/CIRCULATIONAHA.114.013116
18. Moayyeri A, Cheung C-L, Tan KC, et al. Metabolomic pathways to 
osteoporosis in middle-aged women: a genome-metabolome-wide 
mendelian randomization study. J Bone Miner Res. 2018;33 
(4):643–650. doi:10.1002/jbmr.3358
19. Miyamoto T, Hirayama A, Sato Y, et al. A serum 
metabolomics-based profile in low bone mineral density postmeno-
pausal women. Bone. 2017;95:1–4. doi:10.1016/j.bone.2016.10.027
20. Qi H, Bao J, An G, et al. Association between the metabolome and 
bone mineral density in pre- and post-menopausal chinese women 
using GC-MS. Mol Biosyst. 2016;12(7):2265–2275. doi:10.1039/ 
C6MB00181E
21. Soininen P, Kangas AJ, Wurtz P, Suna T, Ala-Korpela M. 
Quantitative serum nuclear magnetic resonance metabolomics in 
cardiovascular epidemiology and genetics. Circ Cardiovasc Genet. 
2015;8(1):192–206. doi:10.1161/CIRCGENETICS.114.000216
22. Bonjour P, Clark P, Cooper C, et al. WHO scientific group on the 
assessment of osteoporosis at primary health care level. J Med. 
2004;7:2020.
23. Aguilar-Shea AL, Gallardo-Mayo C, Garrido-Elustondo S, Calvo- 
Manuel E, Zamorano-Gomez JL. Carotid intima-media thickness as 
a screening tool in cardiovascular primary prevention. Eur J Clin 
Invest. 2011;41(5):521–526. doi:10.1111/j.1365-2362.2010.02440.x
24. Raynor LA, Schreiner PJ, Loria CM, Carr JJ, Pletcher MJ, 
Shikany JM. Associations of retrospective and concurrent lipid levels 
with subclinical atherosclerosis prediction after 20 years of follow-up 
: the Coronary Artery Risk Development in Young Adults (CARDIA) 
study. Annals of Epidemiology. 2013;23(8):492–497. doi:10.1016/j. 
annepidem.2013.06.003
25. Prenner SB, Mulvey CK, Ferguson JF, Rickels MR, Bhatt AB, 
Reilly MP. Very low density lipoprotein cholesterol associates with 
coronary artery calcification in type 2 diabetes beyond circulating 
levels of triglycerides. Atherosclerosis. 2014;236(2):244–250. 
doi:10.1016/j.atherosclerosis.2014.07.008
26. Sivas F, Alemdaroglu E, Elverici E, Kulug T, Ozoran K. Serum lipid 
profile: its relationship with osteoporotic vertebrae fractures and bone 
mineral density in turkish postmenopausal women. Rheumatol Int. 
2009;29(8):885–890. doi:10.1007/s00296-008-0784-4
27. Shen H, Damcott CM, Rampersaud E, et al. Familial defective 
apolipoprotein B-100 and increased low-density lipoprotein choles-
terol and coronary artery calcification in the old order amish. Arch 
Intern Med. 2010;170(20):1850–1855. doi:10.1001/archinternmed. 
2010.384
28. Yerges-Armstrong LM, Shen H, Ryan KA, Streeten EA, Shuldiner AR, 
Mitchell BD. Decreased bone mineral density in subjects carrying 
familial defective apolipoprotein B-100. J Clin Endocrinol Metab. 
2013;98(12):1999–2005. doi:10.1210/jc.2013-2471
29. Sabour H, Nazari M, Latifi S, et al. The relationship between dietary 
intakes of amino acids and bone mineral density among individuals 
with spinal cord injury. Oman Med J. 2016;31(1):22–28. doi:10.5001/ 
omj.2016.05
30. Bray GA, Redman LM, de Jonge L, Rood J, Sutton EF, Smith SR. 
Plasma amino acids during 8 weeks of overfeeding: relation to diet 
body composition and fat cell size in the PROOF study. Obesity. 
2018;26(2):324–331. doi:10.1002/oby.22087
31. Murr C, Grammer TB, Meinitzer A, Kleber ME, Marz W, Fuchs D. 
Immune activation and inflammation in patients with cardiovascular 
disease are associated with higher phenylalanine to tyrosine ratios: 
the ludwigshafen risk and cardiovascular health study. J Amino Acids. 
2014;2014:783730. doi:10.1155/2014/783730
32. Deidda M, Piras C, Cadeddu Dessalvi C, et al. Blood metabolomic 
fingerprint is distinct in healthy coronary and in stenosing or micro-
vascular ischemic heart disease. J Transl Med. 2017;15(1):112. 
doi:10.1186/s12967-017-1215-7
33. Boogaard A, Griffioen M, Cohen LH. Regulation of 3-hydroxy- 
3-methylglutaryl-coenzyme A reductase in human hepatoma cell 
line hep G2. Effects of inhibitors of cholesterol synthesis on enzyme 
activity. Biochem J. 1987;241(2):345–351. doi:10.1042/bj2410345
34. Rosvall M, Persson M, Ostling G, et al. Risk factors for the progres-
sion of carotid intima-media thickness over a 16-year follow-up 
period: the Malmö Diet and Cancer Study. Atherosclerosis. 
2015;239(2):615–621. doi:10.1016/j.atherosclerosis.2015.01.030
35. Li GH, Cheung CL, Au PC, Tan KC, Wong IC, Sham PC. Positive 
effects of low LDL-C and statins on bone mineral density: an inte-
grated epidemiological observation analysis and mendelian randomi-
zation study. Int J Epidemiol. 2019;dyz145.
36. Warburton DE. Health benefits of physical activity: the evidence. 
CMAJ. 2006;174(6):801–809. doi:10.1503/cmaj.051351
37. Feuchtner G, Langer C, Barbieri F, et al. Relationship of exercise to 
coronary artery disease extent, severity and plaque type: a coronary com-
puted tomography angiography study. Journal of Cardiovascular 
Computed Tomography. 2019;13(3):34–40. doi:10.1016/j.jcct. 
2019.02.001
Vascular Health and Risk Management                                                                                             Dovepress 
Publish your work in this journal 
Vascular Health and Risk Management is an international, peer- 
reviewed journal of therapeutics and risk management, focusing on 
concise rapid reporting of clinical studies on the processes involved in 
the maintenance of vascular health; the monitoring, prevention and 
treatment of vascular disease and its sequelae; and the involvement  
of metabolic disorders, particularly diabetes. This journal is indexed 
on PubMed Central and MedLine. The manuscript management 
system is completely online and includes a very quick and fair peer- 
review system, which is all easy to use. Visit http://www.dovepress. 
com/testimonials.php to read real quotes from published authors.  
Submit your manuscript here: https://www.dovepress.com/vascular-health-and-risk-management-journal
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                       
Vascular Health and Risk Management 2020:16 524




































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
